Abstract
Flavonoids belong to polyphenolic secondary metabolites with broad-spectrum pharmacological activities and extensive biological effects, and the most prominent activity is their potential role as anticancer agents. In recent years, flavonoids and their synthetic analogues have been intensely investigated in the treatment of ovarian, breast, cervical, pancreatic, and prostate cancer. To some extent, chemical structures of flavonoids will influence their anticancer activities. Thus, some new analogues based on the structural skeleton of these flavonoids have been synthesized and investigated. This review presents recent advances on the patents concerning of the natural flavonoids and their synthetic analogues in the treatment of cancers, and new synthetic approaches and possible structure-activity relationships of flavonoids are also briefly summarized.
Keywords: Anticancer, flavonoids, synthetic analogue, flavones, isoflavone, flavonol, flavanol, anthocyanin, chalcone
Recent Patents on Anti-Cancer Drug Discovery
Title: Flavonoids: Recent Advances as Anticancer Drugs
Volume: 5 Issue: 2
Author(s): Hai L. Liu, Wen B. Jiang and Meng X. Xie
Affiliation:
Keywords: Anticancer, flavonoids, synthetic analogue, flavones, isoflavone, flavonol, flavanol, anthocyanin, chalcone
Abstract: Flavonoids belong to polyphenolic secondary metabolites with broad-spectrum pharmacological activities and extensive biological effects, and the most prominent activity is their potential role as anticancer agents. In recent years, flavonoids and their synthetic analogues have been intensely investigated in the treatment of ovarian, breast, cervical, pancreatic, and prostate cancer. To some extent, chemical structures of flavonoids will influence their anticancer activities. Thus, some new analogues based on the structural skeleton of these flavonoids have been synthesized and investigated. This review presents recent advances on the patents concerning of the natural flavonoids and their synthetic analogues in the treatment of cancers, and new synthetic approaches and possible structure-activity relationships of flavonoids are also briefly summarized.
Export Options
About this article
Cite this article as:
Liu L. Hai, Jiang B. Wen and Xie X. Meng, Flavonoids: Recent Advances as Anticancer Drugs, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936261
DOI https://dx.doi.org/10.2174/157489210790936261 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Editorial (Thematic Issue: Mitochondria and Subcellular Organelles as Treatment Targets Against Pathological Conditions)
Current Pharmaceutical Design Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Toward Inhibitors of Protein Tyrosine Phosphatases for Cancer Treatment
Current Enzyme Inhibition T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry Emerging Targets For Prostate Adenocarcinoma Therapy: How Molecular Biology May Drive Towards a More Tailored Approach
Current Drug Targets CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets A Novel Probiotic Formula, BIOCG, Protects Against Alzheimer’s-Related Cognitive Deficits via Regulation of Dendritic Spine Dynamics
Current Alzheimer Research Exosomes: A Novel Therapeutic Paradigm for the Treatment of Depression
Current Drug Targets Trabectedin as a New Chemotherapy Option in the Treatment of Relapsed Platinum Sensitive Ovarian Cancer
Current Pharmaceutical Design E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions
Current Drug Metabolism Synthesis and Evaluation of <sup>198</sup>Au/PAMAM-MPEG-FA against Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Structural and Functional Diversity of Estrogen Receptor Ligands
Current Topics in Medicinal Chemistry How Much is Enough? Modulation of Dose-Response Curve for Steroid Receptor-Regulated Gene Expression by Changing Concentrations of Transcription Factor
Current Topics in Medicinal Chemistry Synthesis and Anti-thyroid Cancer Effect of Iodo-chrysin Derivatives
Medicinal Chemistry Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Diagnostic und Therapeutic Value of Cell-free Circulating DNA as a Non-invasive Biomarker in Patients with Prostate Cancer
Current Cancer Therapy Reviews